Analysis of Debt
Total Debt (Carrying Amount)
Abbott Laboratories, balance sheet: debt
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Debt item | Description | The company |
|---|---|---|
| Total debt (carrying amount) | Sum of the carrying values as of the balance sheet date of all debt plus capital lease obligations. | Abbott Laboratories total debt decreased from 2022 to 2023 and from 2023 to 2024. |
Total Debt (Fair Value)
| Dec 31, 2024 | |
|---|---|
| Selected Financial Data (US$ in millions) | |
| Short-term borrowings | —) |
| Long-term debt, including current maturities | 13,710) |
| Total debt (fair value) | 13,710) |
| Financial Ratio | |
| Debt, fair value to carrying amount ratio | 0.97 |
Based on: 10-K (reporting date: 2024-12-31).
Weighted-average Interest Rate on Debt
Weighted-average interest rate on debt: 3.82%
| Interest rate | Debt amount1 | Interest rate × Debt amount | Weighted-average interest rate2 |
|---|---|---|---|
| 2.95% | 1,000) | 30) | |
| 3.88% | 500) | 19) | |
| 1.50% | 1,188) | 18) | |
| 3.75% | 1,700) | 64) | |
| 0.38% | 615) | 2) | |
| 1.15% | 650) | 7) | |
| 1.40% | 650) | 9) | |
| 4.75% | 1,650) | 78) | |
| 6.15% | 547) | 34) | |
| 6.00% | 515) | 31) | |
| 5.30% | 694) | 37) | |
| 4.75% | 700) | 33) | |
| 4.90% | 3,250) | 159) | |
| Total | 13,659) | 522) | |
| 3.82% | |||
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in millions
2 Weighted-average interest rate = 100 × 522 ÷ 13,659 = 3.82%